资讯

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...